David Stanley Bailey
Fondatore presso IOTA Pharmaceuticals Ltd.
Profilo
David Stanley Bailey was the founder of De Novo Pharmaceuticals Ltd.
(founded in 1999), Purely Proteins Ltd.
(founded in 2002), and IOTA Pharmaceuticals Ltd.
(founded in 2007) where he held the titles of Chief Executive Officer and Director.
He also held former positions as a Principal at Incyte Corp.
and Pfizer Inc., as well as at the University of London.
Dr. Bailey received a doctorate degree from the University of Cambridge.
Posizioni attive di David Stanley Bailey
| Società | Posizione | Inizio |
|---|---|---|
IOTA Pharmaceuticals Ltd.
 IOTA Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology IOTA Pharmaceuticals Ltd. is a pharmaceutical discovery services company. Its services include virtual screening packages, surface Plasmon resonance (SPR) screening package, high-sensitivity biochemical screening package, nuclear magnetic resonance (NMR) screening package, and co-crystallography of fragment-based leads. The company was founded by Paul England and David Bailey in 2007 and is headquartered in Cambridge, the United Kingdom. | Fondatore | 01/01/2007 |
Precedenti posizioni note di David Stanley Bailey
| Società | Posizione | Fine |
|---|---|---|
De Novo Pharmaceuticals Ltd.
 De Novo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom. | Fondatore | - |
| INCYTE CORPORATION | Corporate Officer/Principal | - |
| University of London | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Purely Proteins Ltd.
 Purely Proteins Ltd. Pharmaceuticals: MajorHealth Technology Purely Proteins Ltd. provided supportive services for drug discovery. The firm also offered range of protein-based tools to aid drug discovery, research and development. The company was founded by David Bailey, Geeta Gupta, Christopher Robin Lowe and David J. Parry-Smith on July 16, 2002 and was headquartered in Madingley, the United Kingdom. | Fondatore | - |
Formazione di David Stanley Bailey
| University of Cambridge | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| PFIZER, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
De Novo Pharmaceuticals Ltd.
De Novo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom. | Health Technology |
Purely Proteins Ltd.
Purely Proteins Ltd. Pharmaceuticals: MajorHealth Technology Purely Proteins Ltd. provided supportive services for drug discovery. The firm also offered range of protein-based tools to aid drug discovery, research and development. The company was founded by David Bailey, Geeta Gupta, Christopher Robin Lowe and David J. Parry-Smith on July 16, 2002 and was headquartered in Madingley, the United Kingdom. | Health Technology |
IOTA Pharmaceuticals Ltd.
IOTA Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology IOTA Pharmaceuticals Ltd. is a pharmaceutical discovery services company. Its services include virtual screening packages, surface Plasmon resonance (SPR) screening package, high-sensitivity biochemical screening package, nuclear magnetic resonance (NMR) screening package, and co-crystallography of fragment-based leads. The company was founded by Paul England and David Bailey in 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- David Stanley Bailey
